vTv Therapeutics (NASDAQ:VTVT) Earns Outperform Rating from Analysts at Evercore

Evercore began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report released on Thursday morning, Marketbeat reports. The brokerage issued an outperform rating and a $44.00 price objective on the biotechnology company’s stock.

Other research analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday. Roth Mkm initiated coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Stock Down 1.3%

Shares of NASDAQ:VTVT opened at $33.28 on Thursday. The firm’s 50 day moving average price is $35.93 and its 200 day moving average price is $29.51. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The stock has a market cap of $131.12 million, a price-to-earnings ratio of -9.93 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.51. The company had revenue of ($0.02) million for the quarter.

Hedge Funds Weigh In On vTv Therapeutics

A number of large investors have recently made changes to their positions in VTVT. 683 Capital Management LLC acquired a new stake in vTv Therapeutics in the fourth quarter valued at $731,000. Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics during the 4th quarter worth $221,000. Geode Capital Management LLC boosted its position in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP boosted its position in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 51,000 shares in the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics News Roundup

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.